Autolus Therapeutics (AUTL) director Robert Azelby details major option grants

Rhea-AI Filing Summary

Autolus Therapeutics plc director Robert Azelby filed an initial ownership report showing three option awards over American Depositary Shares. Each option covers 80,000 underlying shares with exercise prices of $6.84, $3.48 and $2.32, expiring in 2034 and 2035.

According to the footnotes, one grant vested or vests in 36 equal monthly installments commencing on January 9, 2024, another is fully vested and exercisable, and a third vested or vests in twelve equal monthly installments commencing on July 26, 2025. All holdings are reported as direct ownership.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Azelby Robert

(Last) (First) (Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	01/09/2034	American Depositary Shares	80,000	$6.84	D
Share Option (right to buy)	(2)	06/28/2034	American Depositary Shares	80,000	$3.48	D
Share Option (right to buy)	(3)	06/26/2035	American Depositary Shares	80,000	$2.32	D

Explanation of Responses:

1. This option vested or vests in 36 equal monthly installments commencing on January 9, 2024.

2. Fully vested and exercisable.

3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

	/s/ Robert Azelby	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Autolus Therapeutics (AUTL) director Robert Azelby report in this Form 3?

Director Robert Azelby reports initial beneficial ownership of three share option awards over Autolus Therapeutics American Depositary Shares. Each option relates to 80,000 underlying shares, providing detailed disclosure of his equity-based compensation position and vesting structure.

How many Autolus Therapeutics (AUTL) shares are covered by Azelby’s options?

The filing shows three separate share options, each tied to 80,000 underlying American Depositary Shares of Autolus Therapeutics. In total, the options reference 240,000 underlying shares, reflecting his potential future equity exposure if the options are exercised.

What are the exercise prices of Robert Azelby’s Autolus (AUTL) options?

The options have exercise prices of $6.84, $3.48 and $2.32 per underlying American Depositary Share. These prices represent the fixed amounts Azelby would pay per share if he chooses to exercise the respective option grants in the future.

When do Robert Azelby’s Autolus (AUTL) options expire?

The disclosed options expire on January 9, 2034, June 28, 2034 and June 26, 2035. These dates mark the final day each respective option can be exercised before it terminates, assuming all other vesting and service conditions are satisfied.

How do Robert Azelby’s Autolus (AUTL) options vest over time?

One option vested or vests in 36 equal monthly installments starting January 9, 2024. Another is fully vested and exercisable, while a third vested or vests in twelve equal monthly installments commencing July 26, 2025, illustrating staggered vesting schedules.

Are Robert Azelby’s Autolus (AUTL) option holdings direct or indirect?

The Form 3 indicates these Autolus Therapeutics share options are held as direct ownership. Direct ownership means the options are reported in Azelby’s own name, rather than through a trust, family partnership, or other indirect holding structure.